Introduction
Conditioning regimens for Allo-SCT are associated with complications that cause significant morbidity and may affect prognosis.
1 Within 1 week of myeloablative regimens patients develop mucositis, which causes significant discomfort, morbidity and precludes adequate oral intake. 1 Disruption of the gastrointestinal (GI) mucosal barrier facilitates translocation of microorganisms and/or endotoxins into the blood stream. 1, 2 It has been hypothesized that these substances stimulate the production of cytokines by endothelial cells and macrophages, which, in turn, upregulates adhesion molecules and MHC antigens, leading to an increased recognition of host MHC or mHA by mature donor T cells. This is recognized as a major mechanism underlying GVHD. 3 In addition, there are nutritional and metabolic consequences with an overall decrease in body cell mass and negative nitrogen balance. 4 Energy expenditure may also be increased and carbohydrate metabolism impaired. 5, 6 Glutamine, the most abundant free amino acid in the organism, is a nonessential amino acid that has been considered 'conditionally' essential due to its critical role in conditions such as sepsis, trauma and burns, and to the fact that low levels have been correlated with prognosis. 7 The rationale for its use lies in its putative properties on enterocytes and immune cell metabolism regulation. [8] [9] [10] [11] [12] [13] [14] Studies comparing nutritional support with and without glutamine supplementation in SCT have been conducted with the assumption stated above for critical conditions, that is, glutamine exerts a protective effect on gut mucosal barrier and stimulates immune cell proliferation. Indeed, end points such as infection rate, hospital stay and nitrogen balance have been shown to improve in some studies, but others have failed to demonstrate positive outcomes. [15] [16] [17] [18] [19] [20] Inclusion of non-homogeneous populations (with a variety of diagnoses, prognoses and types of SCT) might have contributed to the different results observed. 21 To evaluate the role of glutamine on clinical outcomes after myeloablative Allo-SCT, we conducted a double-blind randomized study comparing patients who received glutamine-enriched parenteral nutrition (GlPN) with patients who received standard parenteral nutrition (PN). Intestinal permeability (IP) tests were also performed to evaluate a possible protective effect of glutamine on GI mucosal barrier.
Patients and methods

Patients
Fifty-three consecutive leukemia patients aged 18-64 who underwent HLA-identical sibling Allo-SCT after myeloablative conditioning regimen were included. After providing informed consent, patients were randomly assigned either to receive GlPN or standard PN. Random numbers were generated by the statistical program EPIINFO 6.04 and were drawn to assign patients to one of the groups. The randomization was performed by the pharmacist in charge of preparing the PN. Patients and the clinical transplantation team were blinded for the assigned arm. PN solutions were not identified for glutamine supplementation.
Patients were classified as having either low-or high-risk disease. Low-risk patients were those with CML in first chronic phase, acute leukemia in first remission and myelodysplasia with refractory anemia with or without ringed sideroblasts, whereas high-risk patients were CML in accelerated phase, acute leukemias beyond first remission and myelodysplasia beyond refractory anemia.
Patients undergoing Allo-SCT for benign diseases and those who presented solid tumors or lymphomas were excluded. Patients with renal failure, cirrhosis, congestive heart failure, nephrotic syndrome or other diseases that interfered with the absorption and flux of water and solutes were also excluded to avoid interference with IP tests.
Conditioning regimen and GVHD prophylaxis
Conditioning and GVHD prophylaxis were classified dichotomicaly as standard or non-standard. Standard conditioning included the combination of BU 16 mg/kg and CY 120 mg/kg. Non-standard conditioning involved the use of fludarabine or etoposide, substituting for or in association with the standard regimen drugs. As for GVHD prophylaxis, the standard regimen was the one that involved the use of CYA and MTX, and non-standard regimen the one in which MTX was replaced by corticosteroids. First-line treatment for acute GVHD was i.v. methylprednisolone 2 mg/kg for all patients.
Parenteral nutrition
Parenteral nutrition was prepared at the hospital pharmacy and delivered in bottles containing a mixture of 500 ml of 10% crystalline amino-acid solution with 500 ml of 50% dextrose and water, yielding a 25% concentration of glucose and a non-protein calorie/nitrogen relation of approximately 110 cal/g. Daily needs of electrolytes, vitamins and microelements were supplied.
A dose of 0.3-0.4 g/kg/day of L-alanyl-L-glutamine dipeptide (Dipeptiven, Fresenius-Kabi, Campinas, Sa˜o Paulo, Brazil), corresponding to 0.2-0.27 g/kg/day of glutamine, was added to PN of GlPN patients during the first week of transplantation, that is, from the day of stem cell infusion (D0) to the sixth day after infusion (D þ 6). The corresponding amount of standard amino acids was removed from the solution to prepare isonitrogenous solutions for both groups. Patients were allowed to eat ad libitum. Patients who needed to continue on PN after D þ 6 were kept on standard solutions.
Intestinal permeability study
Intestinal permeability tests with lactulose and mannitol were performed in an attempt to measure conditioningrelated intestinal mucosal damage. When allowed by patients' clinical condition, IP tests were performed on admission, D þ 6 and D þ 14. IP was measured in a 6 h urine sample that was collected after ingestion of a 120 ml isosmolar solution that contained 6.0 g of lactulose (Sigma-Aldrich, Steinheim, Germany) and 3.0 g of mannitol (Sigma-Aldrich), offered after a 9 h night fast. Before the 6 h collection, patients were instructed to void urine. The 6 h urine volume was registered and 50 ml of the urine was stored in vials containing 12 mg of timerosal (Labsynth, Sa˜o Paulo, Brazil) to prevent bacterial growth and was stored at À20 1C. On the day of analysis, samples were thawed in a warm bath and urine was filtered (Millipore filters, 0.2 mm, Sa˜o Paulo, Brazil) and passed over an ion exchange resin (Mixed Bed Resin TMD-8, Sigma Chemical Co., St Louis, MO, USA). Urinary measurements of lactulose and mannitol were performed by means of high performance liquid chromatography (HPLC, Shimadzu, Kyoto, Japan). Specific column and pre-column (Supelco C-610H, Sigma-Aldrich, St Louis, MO, USA) were used for separating the sugars and a mobile phase was applied. Curves were obtained using a refraction index detector. The area under the curve was calculated and plotted against a line graph previously drawn using known concentrations of the sugar, which yielded the concentration of the sample tested. Values of permeability were expressed as lactulose excretion fraction, mannitol excretion fraction and lactulose/mannitol ratio.
Statistical analysis
Primary end points were survival on D þ 100 and D þ 180. Secondary end points included length of stay, clinical infection rate, incidence of grades III-IV acute GVHD, time of neutrophil counts o0.5 Â 10 9 /l and IP as measured by lactulose and mannitol urinary excretion fraction and lactulose/mannitol excretion ratio. As all patients were on prophylactic antimicrobials, clinical infection was defined as a need to add or change antimicrobials as judged by medical staff based on the finding of fever with or without clinical (skin, lung, sinus and so on) and/or microbiological (blood culture, urine culture and so on) signs of infection. Acute GVHD was diagnosed and graded according to the established criteria. 22 The following prognostic variables were analyzed: diagnosis-related risk, conditioning regimen, GVHD prophylaxis regimen, graft source (BM or peripheral blood), gender, donor-receptor gender match and age (bellow and equal or above 40 years). Survival on 100 and 180 days was analyzed using Kaplan-Meier curves, comparing the variable glutamine use in GlPN and PN with the log-rank test. The above dichotomic variables corresponding to prognostic factors were also subjected to Kaplan This study was approved by the Federal University of Minas Gerais Ethics Committee and informed consent was obtained from all patients, according to the Helsinki protocol.
Results
Patients and glutamine supplementation
Fifty-three patients who underwent HLA-identical sibling Allo-SCT, between October 2001 and September 2004, were eligible for the study and were randomized. Another five patients refused to take part and, for three patients, glutamine was not available at the time of randomization. Patients, disease characteristics and treatment were similar between the two groups as summarized in Table 1 .
Patients on GlPN received an average of 23.4 g of glutamine/day, corresponding to 49% of the average protein delivery through PN (47.9 g against 50 g/day on PN group, NS). Oral intake was not recorded.
Clinical outcomes
Overall survival was 74% on D þ 100 and 60% on D þ 180 for the whole population. Survival improved significantly in GlPN group on D þ 100 (85 vs 62%, P ¼ 0.05, log-rank) and on D þ 180 (74 vs 46%, P ¼ 0.03, log-rank; Figure 1 ). As survival analysis for the other variables with prognostic implications on D þ 100 and D þ 180-diagnosis-related risk, conditioning regimen, GVHD prophylaxis regimen, graft source, gender, donor-receptor gender match and age showed P-values above 0.2, Cox regression analysis was not performed.
Timing and causes of death are shown in Table 2 . A higher death rate before D þ 100 and a higher frequency of GVHD as a cause of death occurred in PN, although without statistical significance. Three cases of graft failure occurred in PN. Incidence of acute GVHD was equally distributed between GlPN and PN groups (63 vs 54%, respectively, P ¼ 0.69). There was no difference between GlPN and PN groups for grade III-IV acute GVHD (26 vs 31%, P ¼ 0.93). GI GVHD was present, alone or in combination, in 20 patients, 11 in GlPN and 9 in PN. Grade III-IV GVHD GI involvement occurred in six patients in GlPN and seven patients in PN. Ten patients who died before D þ 100 had GI GVHD. Even though all these deaths may not have been attributed to GVHD, seven (six before D þ 100) out of nine patients who developed GI GVHD in PN group died, whereas only 3 out of 11 patients (all before D þ 100) with gut GVHD died in GlPN. There were 30 cases of chronic GVHD, 16 in GlPN and 14 in PN (59 Â 54%, P NS).
Other secondary end points showed no differences between groups. There was a trend to a lower clinical infection rate (78 vs 92%, P ¼ 0.25) and to a shorter period All IP measurements worsened importantly throughout the study-there were significant rises in lactulose excretion fraction and lactulose/mannitol relationship from admission to D þ 14 and a significant fall in mannitol excretion fraction throughout the study period (Table 3) .
With regard to normal controls, alterations in measurements above the average plus 2 standard deviations were found in most measurements of lactulose/mannitol relationship (39/45, 86.7%) and lactulose excretion fraction (36/44, 81.8%) before conditioning, on admission. In contrast, alterations below average minus 2 standards deviations were found in only 5 out of 44 (11.4%) measurements of mannitol excretion fraction on admission.
Discussion
We observed improved survival, both on D þ 100 and D þ 180, for patients who received glutamine dipeptideenriched PN after a myeloablative allo-SCT. We were able to enroll a homogeneous population with respect to age, diagnosis, conditioning, GVHD prophylaxis and graft source. The predominance of CML, which was in part responsible for this homogeneity, occurred because imatinib was not available for the Brazilian public health-care system as first-line treatment at the time the study was carried out.
As shown in Table 2 , most deaths occurred before D þ 100, predominantly in PN-a 15% death rate in GlPN against 38% in PN, P ¼ 0.10. In contrast, death rate after D þ 100 was similar in number in both groups-11% in GlPN against 15% in PN, P ¼ 0.70. If we consider one relapse in each group, which should not be affected by glutamine, these results are more striking. Even though numbers are too small to show statistical significance, they may suggest that a putative glutamine effect should have occurred before D þ 100. Because of the small sample size, there is, however, a possibility that the observed effects of glutamine on the study population may have occurred by chance.
An analysis of causes of death showed that the main causes in this period were GVHD and infection. Even though severe, grade III-IV, acute GVHD rate did not show statistical differences between groups, 75% of GVHD associated deaths (6/8) occurred in PN group, five of them before D þ 100, which might lead us to consider the possibility of a protective effect of glutamine supplementation in this situation. A lower, albeit nonsignificant, incidence of grade X2 GVHD for glutamine-supplemented SCT patients has been found by others. 20 Outcome comparisons in glutamine supplementation studies in SCT have been hampered by the lack of Table 2 Timing and causes of death comparability among populations, which have included a mixture of different types of diagnosis and transplants (autologous and/or allogeneic). 21 In addition, these studies have not stated possible differences in disease status, that is, the type and the stage of transplantation. Even though disease stage should impact on late death rates due to relapses, it may also impact on early transplant-related death or treatment failures and should be taken into account when comparing interventions in SCT. 24, 25 A Cochrane collaboration review addressed the issue of glutamine supplementation in SCT, with a favorable conclusion. 26 Among the three articles selected to evaluate PN glutamine supplementation, only one seems to show a more homogeneous population and distribution of patients between groups. 15 It includes only allogeneic transplantation and there are minor differences in diagnoses between groups. The other two present both allogeneic and autologous SCT, including some solid tumors and showing differences in diagnosis between groups. 16, 27 As sample sizes are small (n ¼ 42, 29 and 34), differences between groups that do not appear as statistically significant may have an influence on final results. These three studies have many subgroups of diagnosis with very small numbers in some of them. With regard to other variables that might have an influence on prognosis, only few prognostic factors were specifically addressed: donors' kinship in one study and conditioning regimen (the frequency of distribution was not always stated). Two studies comprised a mixture of allogeneic and autologous SCT. 16, 27 As there has been a suggestion that autologous transplant patients who receive glutamine fare worse than those on standard PN, a fact that has not been observed in allogeneic transplant patients, one may speculate that results of glutamine supplementation in allogeneic transplantation may be underestimated due to negative results with autologous transplantation. 19 Anyway, in accordance with previous statement, it seems difficult to draw any conclusion on the efficacy of glutamine based on previous studies. 21 Contrary to our initial hypothesis, glutamine seemed to exert no effect on gut integrity as evaluated by IP tests, as already shown by others. 20, 28, 29 A protective role on GI tract mucosa that is specific to glutamine is still under scrutiny by the literature 30, 31 and if such an effect indeed exists, one possible explanation for its absence is that the damage to the mucosa is so intense in the first few weeks after conditioning that a protective effect could not overcome it.
Causes of death Timing
Analysis of IP measurements shows, as has been demonstrated before, 26, 32 that these measurements were already abnormal before conditioning in most patients. Functional (as measured by lactulose excretion) in addition to anatomical (measured by mannitol) integrity of GI mucosa could be the cause of IP alterations on admission, 33, 34 as disease itself may be responsible for it, and not only previous chemotherapy. Considering the possible effect of initial endotoxin and cytokine liberation on GVHD pathogenesis, a role of this preconditioning SCT 'leaky' gut should be evaluated.
Intestinal permeability measurements worsened importantly throughout the study and remained impaired on the latest evaluation, when symptoms of mucosites might have abated, a type of behavior that has been demonstrated before. 29 Our IP values show differences from literature specifically lactulose excretion rate, and, as a consequence, lactulose/mannitol relationship, a fact that could be attributed to different test conditions and methodology, and geographical differences. 35, 36 Even though differences from reported IP values must be pointed out, the qualitative behavior of the probes is similar to what has been found by others. 20, 28, 29 If the effects of glutamine on GI mucosal barrier could not be shown to account for mortality reduction, immune and metabolic effects should be evoked. Previous studies have shown a reduction in mortality and complication rates 6 months after GlPN in intensive care unit populations. Even though GI mucosal barrier evaluations were not carried out, immune enhancement was brought up as a possible explanation for better outcomes. There is a great deal of in vivo and in vitro experimental evidence relating increased glutamine availability to animals or to cultivated human or animal lymphocytes, macrophages or neutrophils with increased cell proliferation, phagocytic activity, cytokine production, antigen presentation, superoxide production and diminished neutrophil apoptosis. [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] T-cell and CD4 count and T-cell DNA synthesis as surrogate end points have been affected by glutamine provision to postoperative patients. 48, 49 Flow cytometry lymphocyte count performed 1-2 weeks after discharge from SCT have shown increased CD4 and CD8 counts in response to glutamine. 50 Another possible role of glutamine in the immune system would be an immunomodulatory action on intestinal immune cells; especially in gut-associated lymphoid tissue. PN with glutamine has been associated with preservation of intestinal IgA and anti-inflammatory cytokines IL-4 and IL-10 levels in animals in contrast to low levels of these substances found in animals fed with PN without glutamine. 51 Also, lipopolysaccharide-stimulated lymphoid tissue from intestinal lamina propria was able to preserve IL-4 and IL-10 mRNA expression in response to GlPN, in contrast to standard PN. 52 Expression of vascular adhesion molecules that promote neutrophil adhesion to vascular wall and tissue injury has been shown to be reduced in animals that received glutamine, and this effect seems to be associated with higher levels of anti-inflammatory cytokines. A reduction of levels of proinflammatory IL-8 and IL-6 have been found in glutamine-treated specimens of intestinal biopsies from volunteers fed with glutamine. 53 Mononuclear cells from pancreatitis patients treated with glutamine also showed reduced production of IL-8. 54 Others have shown reduced levels of C-reactive protein and increased lymphocyte counts in pancreatitis in response to glutamine supplementation. 55 These effects suggest that glutamine may induce a Th2 type response in gutassociated lymphoid tissue lymphocytes in response to some noxious stimuli. If this is true and if the paradigm of the Th1 type of polarization of donor lymphocytes still holds as an important explanation for acute GVHD induction, one might speculate on a possible contribution of glutamine toward the stimulation of a Th2 type of response by activated donor lymphocytes. This immunomodulatory action might be a possible explanation for the increased early survival in glutaminesupplemented patients, especially as it relates to effects on cytokine storm following conditioning and its role on pathogenesis of GVHD.
Metabolic effects, especially better nitrogen balance and lower plasma glucose levels have also been evoked as important glutamine actions in intensive care population and should be evaluated as a possible explanation for a better outcome. Better nitrogen balance has already been shown in SCT glutamine-supplemented patients. 16 Worst glycemic control has been found in PN-treated SCT patients and it has been related to increased morbidity. 56 In conclusion, glutamine-supplemented PN was efficacious in reducing short-term mortality in a relatively homogeneous Allo-SCT population. This effect could not be attributed to a preservation of gut mucosal integrity, as IP measurements did not show differences between groups. In contrast, the bulk of experimental data relating glutamine to immune function would suggest a possible mechanism of action for the amino acid. Of special interest, a reduction on the incidence of death-related GVHD as shown here, albeit lacking statistical significance, may suggest an immunomodulatory role of glutamine in SCT that might deserve further research.
